Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. (Q35148777)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. |
scientific article |
Statements
1 reference
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. (English)
1 reference
Geir Tjønnfjord
1 reference
Jan Walewski
1 reference
Eva Kimby
1 reference
Aaron Polliack
1 reference
Christian H Geisler
1 reference
Mars B van T' Veer
1 reference
Jesper Jurlander
1 reference
Maija Itälä Remes
1 reference
Tomas Kozak
1 reference
Ka Lung Wu
1 reference
Shulamiet Wittebol
1 reference
Martine C J Abrahamse-Testroote
1 reference
Jeanette Doorduijn
1 reference
Wendimagegn Ghidey Alemayehu
1 reference
Marinus H J van Oers
1 reference
15 April 2014
1 reference
Identifiers
1 reference